Phathom Pharmaceuticals, Inc. Debt/Equity

Debt/Equity of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending September 29, 2021 was 0.87 (a 132.17% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity increased by 244.99%
  • Annual Debt/Equity for 2020 was 0.25 (a 144.0% increase from previous year)
  • Annual Debt/Equity for 2019 was 0.1 (a -106.82% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Phathom Pharmaceuticals, Inc.

Most recent Debt/Equityof PHAT including historical data for past 10 years.

Interactive Chart of Debt/Equity of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.87 0.37 0.3
2020 0.25 0.31 0.25 0.22 0.25
2019 0.1 -0.77 0.0 0.0 0.1
2018 -1.52 0.0 -1.52

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.